LEXINGTON, Mass., Dec. 8, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic-resistant genes, today announced the publication of a -Reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America.
“We are grateful to these distinguished authors for reinforcing the CDC’s call for the adoption and implementation of early and accurate microbial diagnosis to guide targeted antimicrobial therapy, directly aligning with the value proposition of T2 technology,” said John Sperzel, President and CEO of T2 Biosystems. “Sepsis continues to exact a high human and financial cost, disproportionately affecting minorities and underserved communities. We believe our FDA-cleared T2Dx instrument, T2Bacteria panel and T2Candida panel can help improve the standard of care and offer the ideal solution to accurately detect sepsis-causing pathogens and provide the information necessary for clinicians to achieve faster and more targeted antimicrobial therapy.”
Title: Facing the challenges of sepsis in severe cases of COVID-19: a call to arms
Authors: Thomas J. Walsh, Rick A. Bright, Aparna Ahuja, Matthew W. McCarthy, Richard A. Marfuggi, and Steven Q. Simpson
Daily: Oxford University Press on behalf of the Infectious Diseases Society of America, 2022
This perspective reviewed the burden of bacterial and fungal sepsis from epidemiological and personal standpoints, highlighting the convergence of risk factors and clinical manifestations of severe COVID-19 and sepsis, which represents a daunting challenge for an accurate diagnosis.
Article Highlights:
-
The global burden of sepsis, from any cause, is estimated to be 50 million cases per year and is the cause of 1 in 5 deaths, including approximately 350,000 Americans and 680,000 Europeans each year.
-
The US spends approximately $62 billion annually treating sepsis, making it the most expensive hospital therapeutic cost.
-
Sepsis is a serious health hazard that requires timely and adequate treatment; survival decreases by 7.6% for each hour of delay in the administration of adequate therapy
-
Critically ill hospitalized patients with SARS-CoV-2 infections are at increased risk of secondary bacterial and fungal infections
-
By improving sepsis outcome, disparate COVID-19 outcomes in historically disadvantaged minorities may also be improved; Native Americans, Pacific Islander Americans, and African Americans have the highest death rates from COVID-19 infections
-
Although the administration of broad-spectrum antimicrobial therapy in the absence of a microbial diagnosis is the standard of care in the empirical management of sepsis, the strategy is also associated with adverse events and selection of resistant pathogens.
-
Rapid diagnostics must be implemented for use and accessible for use in all segments of the health care system, to shorten exposure time to appropriate and targeted therapy, reduce the likelihood of unnecessary medication administration, improve outcomes, reduce medical care. costs, shorten hospital stay, and reduce the likelihood of developing antimicrobial resistance
-
Underscores CDC’s call for adoption and implementation of early and accurate microbial diagnosis to guide targeted antimicrobial therapy
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping physicians treat patients effectively and faster than ever. T2 Biosystems products include the T2Dx® Instrument, T2 bacteria® Dashboard, the T2Candida® Panel, Resistance T2® and the T2SARS-CoV-2™ panel and are powered by the patented T2 MRI (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, T2Cauris™ Panel, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. For more information please visit www.t2biosystems.com.
forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, including, but not limited to, statements regarding the ability of the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel to rapidly and accurately detect sepsis-causing pathogens and provide information to enable clinicians to achieve more rapid targeted antimicrobial therapy, as well as statements that include the words “expect,” “may,” “should,” “anticipate,” and similar statements of a forward-looking or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are not promises or guarantees, but do involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in forward-looking statements. , including, but not limited to, (i) any inability to (a) obtain anticipated benefits from engagements, contracts or products; (b) successfully execute the strategic priorities; (c) bring products to market; (d) expand the use or adoption of the product; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at the client’s facility; (ii) failure of the first data to predict eventual results; (iii) failure to make or obtain FDA submissions or advance clearances within the expected timeframes or at all; or (iv) the factors discussed in Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission, or SEC, on March 23 of 2022, and other filings the Company makes with the SEC from time to time, including our quarterly reports on form 10-Q and current reports on form 8-K. These and other important factors could cause actual results to differ materially from those indicated in the forward-looking statements made in this press release. Any forward-looking statements represent management estimates as of the date of this news release. Although the Company may choose to update such forward-looking statements at some time in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Therefore, no one should assume that the Company’s silence over time means that actual facts are being confirmed, as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon to represent the views of the Company as of any date after the date of this press release.
Contact for investors:
Philip Trip Taylor, Gilmartin Group
[email protected]
415-937-5406
